On December 4, 2015 Akeso Biopharma Inc. (Akeso) reported that the company has entered into a collaboration with MSD, known as Merck (NYSE:MRK) in the United States and Canada, to research, develop and commercialize immuno-oncology therapeutics (Press release, Akeso Biopharma, DEC 4, 2015, View Source [SID1234525263]). According to this agreement, MSD will obtain exclusive worldwide rights to develop and commercialize Akeso’s compound AK-107, an immune checkpoint blocking antibody discovered by Akeso in China. Under the terms of the agreement, Akeso will receive an upfront payment from MSD and up to $200 million in development and commercialization milestone payments. Additional details were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to establish this collaboration with MSD, the global leader in immuno-oncology. Through this collaboration, we will combine Akeso’s unique Biologics discovery platform with MSD’s well-established late-stage clinical and commercialization strengths to rapidly advance Akeso’s compound AK-107 to the global markets. This collaboration demonstrates our companies’ commitment to bring innovative therapies to the market to address unmet medical needs for cancer patients worldwide," said Dr. Michelle Y. Xia, Chairman of the Board and Chief Executive Officer of Akeso.
"We look forward to working with MSD and we will continue to explore opportunities to work together in the field of innovative biologics." "The collaboration with Akeso builds on our existing strength in the field of immuno-oncology as we remain focused on advancing the care of people with cancer by stimulating tumor-directed immune responses," said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories. "The addition of this immune checkpoint blocking antibody, AK-107, reinforces our commitment to exploring combination approaches across tumor types."